NasdaqCM - Delayed Quote • USD
NeoGenomics, Inc. (NEO)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 4:02 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 11 | 12 |
| Avg. Estimate | -0.05 | -0.01 | -0.01 | 0.14 |
| Low Estimate | -0.11 | -0.06 | -0.19 | 0.06 |
| High Estimate | -0.02 | 0.01 | 0.08 | 0.2 |
| Year Ago EPS | -0.09 | -0.05 | -0.12 | -0.01 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 13 | 12 |
| Avg. Estimate | 149.89M | 162.65M | 654.56M | 718.47M |
| Low Estimate | 148.1M | 161.1M | 651M | 707.1M |
| High Estimate | 152M | 164.22M | 659M | 727.08M |
| Year Ago Sales | 137.22M | 137.42M | 591.64M | 654.56M |
| Sales Growth (year/est) | 9.20% | 18.40% | 10.60% | 9.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.15 | -0.11 | -0.07 | -0.02 |
| EPS Actual | -0.09 | -0.05 | 0 | 0.03 |
| Difference | 0.06 | 0.06 | 0.07 | 0.05 |
| Surprise % | 40.00% | 54.50% | 100.00% | 250.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.05 | -0.01 | -0.01 | 0.14 |
| 7 Days Ago | -0.05 | -0.01 | -0.01 | 0.14 |
| 30 Days Ago | -0.05 | -0.01 | -0.01 | 0.14 |
| 60 Days Ago | -0.05 | -0.01 | -0.01 | 0.13 |
| 90 Days Ago | -0.05 | -0.03 | -0.09 | 0.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | NEO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 44.40% | -- | -- | 0.40% |
| Next Qtr. | 80.00% | -- | -- | 9.90% |
| Current Year | 91.70% | -- | -- | 4.30% |
| Next Year | 1,500.00% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 151.20% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 33.63% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Piper Sandler: Overweight to Overweight | 2/26/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 2/22/2024 |
| Maintains | Needham: Buy to Buy | 2/21/2024 |
| Maintains | TD Cowen: Outperform to Outperform | 12/29/2023 |
| Maintains | BTIG: Buy to Buy | 12/29/2023 |
| Reiterates | Needham: Buy to Buy | 12/28/2023 |
Related Tickers
NTRA Natera, Inc.
91.04
+2.74%
MYGN Myriad Genetics, Inc.
18.60
+0.59%
GH Guardant Health, Inc.
17.34
-1.42%
NEOG Neogen Corporation
12.31
+4.50%
CDNA CareDx, Inc
8.23
+0.73%
VCYT Veracyte, Inc.
19.83
-0.10%
PSNL Personalis, Inc.
1.3800
+9.52%
SHC Sotera Health Company
11.38
+2.61%
DGX Quest Diagnostics Incorporated
136.70
+5.08%
EXAS Exact Sciences Corporation
63.53
+1.79%